<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01174446</url>
  </required_header>
  <id_info>
    <org_study_id>250901</org_study_id>
    <secondary_id>2009-016720-31</secondary_id>
    <nct_id>NCT01174446</nct_id>
  </id_info>
  <brief_title>Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients</brief_title>
  <official_title>Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pivotal Phase 1/3 study is to determine the pharmacokinetic (PK)
      parameters, the hemostatic efficacy, and the safety of BAX 326, a recombinant factor IX, in
      previously treated patients (PTPs) with severe and moderately severe hemophilia B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Part 1- Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Per Dose</measure>
    <time_frame>72 hours</time_frame>
    <description>Computed using the linear trapezoidal method. The concentration at 72 hours was interpolated from the two nearest sampling time points or extrapolated using the last quantifiable concentration and the terminal rate constant λz. λz was estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study Parts 1 and 3: Area Under the Plasma Concentration/Time Curve From Time 0 to Infinity Per Dose (AUC0-∞/ Dose)</measure>
    <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
    <description>Defined as (AUC0-t + Ct)/ λz/ dose, where t is the time of last quantifiable concentration, Ct is the last quantifiable concentration. λz will be estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Parts 1 and 3: Mean Residence Time (MRT)</measure>
    <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
    <description>Computed as Area under the moment curve 0-∞ (AUMC0-∞) / AUC0-∞- TI/2, where AUMC0-∞ will be determined in a similar manner as AUC0-∞ and TI represents infusion duration [hr]
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Parts 1 and 3: Clearance (CL)</measure>
    <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
    <description>Computed as Dose/ AUC0-∞.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Parts 1 and 3: Incremental Recovery at Cmax (IR at Cmax)</measure>
    <time_frame>0-30 minutes before infusion up to 1 hour post-infusion</time_frame>
    <description>Defined as (Cmax - Cpre-infusion)/Dose, where maximum concentration (Cmax) will be determined as the highest concentration achieved within one hour after infusion.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Recovery (IR) at 30 Minutes Over Time</measure>
    <time_frame>0-30 minutes before infusion and 30 minutes post-infusion</time_frame>
    <description>IR at 30 Minutes was measured at the following time points during the study:
Part 1 or Part 2, Exposure Day (ED) 1. (If participant was present for Study Part 1, then ED 1 from Part 1 was used. If Participant entered study in Study Part 2, then ED 1 from Part 2 was used.)
Part 2: Week 5
Part 2: Week 13
Part 2 or Part 3: Week 26 (Week 26 of study participation)
Study Completion or Termination Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Incremental Recovery (IR) at 30 Minutes Over Time</measure>
    <time_frame>0-30 minutes before infusion and 30 minutes post-infusion</time_frame>
    <description>The median changes in IR at 30 Minutes, calculated as the change in IR value from exposure day 1 (ED1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Parts 1 and 3: Half Life (T 1/2)</measure>
    <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
    <description>Elimination phase half-life will be determined as ln2/ λz.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Parts 1 and 3: Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
    <description>Vss computed as CL·MRT.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Part 2: Annualized Bleed Rate (ABR) During Treatment With BAX326</measure>
    <time_frame>Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks)</time_frame>
    <description>ABR during prophylaxis (twice-weekly) in Part 2 was calculated as (Number of bleeding episodes/observed treatment period in days) * 365.25. The treatment period on prophylaxis was defined as time between the first and the last prophylactic infusions and ABR on prophylaxis was calculated for participants who received a minimum of 3 months of prophylactic treatment with BAX326.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Episodes Treated With 1, 2 or ≥3 Infusions of BAX326 by Bleeding Site and Cause</measure>
    <time_frame>Study Part 2 = 26 weeks ± 1 week (Study Part 2 began at week 3-5)</time_frame>
    <description>The number of bleeding episodes treated with 1, 2, or ≥3 infusions of BAX326 to achieve adequate hemostasis. Only infusions required until resolution of bleed were considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemostatic Efficacy at Resolution of All Bleeding Episodes (BEs) Treated With BAX326 by Bleeding Site and Cause</measure>
    <time_frame>At bleed resolution throughout the study period of 22 months (Study Parts 1, 2, and 3)</time_frame>
    <description>Rating Scale for Treatment of BEs (4-point ordinal scale):
Excellent: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion required for the control of bleeding. Administration of further infusions to maintain hemostasis did not affect this scoring.
Good: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution.
Fair: Probable and/or slight relief of pain and slight improvement in signs of bleeding after single infusion. Required more than 1 infusion for complete resolution.
None: No improvement or condition worsens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Weight-adjusted Dose Per Bleeding Episode (BEs) of All BEs Treated With BAX326 by Bleeding Site and Cause</measure>
    <time_frame>Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of BAX326 Per Event Per Participant</measure>
    <time_frame>Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks)</time_frame>
    <description>Weight-adjusted consumption of BAX326 by event per participant, i.e., for prophylactic treatment and for treatment of bleeds until resolution of bleed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of BAX326 Per Participant: Median Number of Infusions Per Month</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week (Prophylaxis and On-Demand period), Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consumption of BAX326 Per Participant: Median Weight-adjusted Consumption Per Month</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week (Prophylaxis and On-Demand period), Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX)</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Total Binding Antibodies of Indeterminate Specificity (Within Assay Variability)</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
    <description>Occurrence of total binding antibodies of indeterminate specificity (within assay variability) to FIX, antibodies to CHO proteins and rFurin is defined by a dilution of 2 or less increase as compared to levels at screening visit (e.g. negative to 1:20 or 1:40).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Treatment Related Total Binding Antibodies</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
    <description>Occurrence of treatment related total binding antibodies to Factor IX (FIX), antibodies to Chinese hamster ovary (CHO) proteins, and recombinant furin (rFurin) is defined by more than 2-dilution increase as compared to levels at screening visit and confirmed specificity (e.g. negative to 1:80)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Severe Allergic Reactions (e.g. Anaphylaxis)</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Thrombotic Events</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Clinical Chemistry</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
    <description>Clinically significant changes in chemistry assessments for Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bicarbonate, Bilirubin, Blood Urea Nitrogen, Chloride, Glucose, Potassium, Protein (Serum), Sodium.
Clinically Significant (CS) defined as:
1. The abnormal value constitutes an adverse event (AE) and,
2. The abnormal value is a symptom of or related to a disease that is already recorded as an AE in Case Report Form (CRF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Hematology</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
    <description>Clinically significant changes in hematology assessments for Basophils, Basophils/Leukocytes, Eosinophils, Eosinophils/Leukocytes, Erythrocyte Mean Corpuscular Hemoglobin Concentration, Erythrocyte Mean Corpuscular Volume, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Lymphocytes/Leukocytes, Monocytes, Monocytes/Leukocytes, Neutrophils, Neutrophils/Leukocytes, Platelets,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Vital Signs</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
    <description>Clinically significant changes in vital signs assessments for pulse rate, systolic/diastolic blood pressure, respiratory rate, body temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Thrombogenic Markers</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
    <description>Clinically significant changes in thrombogenic markers assessments for thrombin-antithrombin (TAT), prothrombin fragment 1.2, and D-dimer as evaluated by an independent Data Monitoring Committee (DMC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events (AEs) After BAX326 Treatment</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, and Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) After BAX326 Treatment</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, and Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Total Index Scores</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQoL (Quality of Life)-5 Dimensions Visual Analogue Scale (EQ-5D VAS) Scores</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Pain Assessment Through a Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Participant rated assessment of health-related quality of life. The VAS Pain Scale rates current health state on a scale from 0 (no pain) to 100 (worst imaginable pain). For the pain scale, a higher score indicates worse pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form (36) Health Survey (SF-36): HRQoL 'Physical Component Score' (PCS)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL 'Mental Health' (MH)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL Physical Functioning' (PF)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL Role-Physical (RP)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL Role-Emotional</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL Bodily Pain</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL Mental Health</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL Vitality</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL Social Functioning</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36: HRQoL General Health</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Questionnaire (PedsQL) Physical Health Summary Score (Ages 12-16)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Questionnaire (PedsQL) Psychosocial Health Summary Score (Ages 12-16)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life Questionnaire (PedsQL) Total Score (Ages 12-16)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL) Disease-specific: Haem-A-QoL</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>The Haem-A-QOL instrument has been developed and used in hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: physical health, sports/leisure, school/work, dealing with hemophilia, and outlook for the future. For the Haem-A-QOL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-Related Quality of Life (HRQoL) Disease-specific: Haemo-QoL - Participants On-Demand (Ages 12-16)</measure>
    <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
    <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Resource Use - Number of Hospitalizations</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Resource Use - Total Days of Hospital Stay</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Resource Use - Emergency Room Visits</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Resource Use - Unscheduled Doctor's Office Visits</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Resource Use - Days Lost From Work or School</measure>
    <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Hemophilia B</condition>
  <arm_group>
    <arm_group_label>BAX 326</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant factor IX (rFIX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BeneFIX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombinant Factor IX (rFIX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BAX 326</intervention_name>
    <description>Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX
Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1</description>
    <arm_group_label>BAX 326</arm_group_label>
    <other_name>Recombinant factor IX (rFIX)</other_name>
    <other_name>RIXUBIS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BeneFIX</intervention_name>
    <description>Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.
BeneFIX only used in Part 1 of this study.
Study Part 2 and 3 only utilized BAX326</description>
    <arm_group_label>BeneFIX</arm_group_label>
    <other_name>Recombinant factor IX (rFIX)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Participant is 12 to 65 years old at the time of screening

          -  Participant and/or legal representative has/have provided signed informed consent

          -  Participant has severe (factor IX (FIX) level &lt; 1%) or moderately severe (FIX level
             1-2%) hemophilia B (based on the one stage activated partial thromboplastin time
             (aPTT) assay), as tested at screening at the central laboratory

          -  Participant is previously treated with plasma-derived or recombinant FIX
             concentrate(s) for a minimum of 150 exposure days (EDs) (based on the participant's
             medical records); if a verifiable, documented history is unavailable, the participant
             can be enrolled if s/he has 100-150 EDs to any FIX product that are not fully
             documented and has participated in Study 050901 for at least 50 EDs to Immunine prior
             to enrollment (not valid for US and Japan).

          -  Participant has no evidence of a history of FIX inhibitors

          -  If the participant is to receive prophylactic treatment, the participant is willing to
             receive prophylactic treatment over a period of 6 months.

          -  If the participant is to receive on-demand treatment, the participant has ≥12
             documented bleeding episodes requiring treatment within 12 months prior to enrollment
             and is willing to receive on-demand treatment for the duration of this study.

        Main Exclusion Criteria:

          -  The participant has a history of FIX inhibitors with a titer ≥0.6 Bethesda Units (BU)
             (as determined by the Nijmegen modification of the Bethesda assay or the assay
             employed in the respective local laboratory) at any time prior to screening

          -  The participant has a detectable FIX inhibitor at screening, with a titer ≥0.6 BU as
             determined by the Nijmegen modification of the Bethesda assay in the central
             laboratory

          -  The participant's weight is &lt; 35 kg or &gt; 120 kg

          -  The participant has a history of allergic reaction, eg, anaphylaxis, following
             exposure to FIX concentrate(s)

          -  The participant has a known hypersensitivity to hamster proteins or recombinant furin
             (rFurin)

          -  The participant has ongoing or recent evidence of a thrombotic disease, fibrinolysis
             or disseminated intravascular coagulation (DIC)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitt Abbuehl, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxter Healthcare Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasilia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
  </removed_countries>
  <results_reference>
    <citation>Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Rusen L, Lamas JL, Oh MS, Chapman M, Fritsch S, Pavlova BG, Wong WY, Abbuehl BE. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level &lt;1%) or moderately severe (FIX level ≤2%) haemophilia B. Haemophilia. 2014 Jan;20(1):15-24. doi: 10.1111/hae.12228. Epub 2013 Jul 9.</citation>
    <PMID>23834666</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2010</study_first_submitted>
  <study_first_submitted_qc>August 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2010</study_first_posted>
  <results_first_submitted>September 20, 2013</results_first_submitted>
  <results_first_submitted_qc>September 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at 32 clinical sites in South America, Europe, Japan, and the United States</recruitment_details>
      <pre_assignment_details>86 enrolled. 1 withdrew consent prior to randomization.
31 were enrolled and randomized in Parts 1-3. Prior to receiving study drug: 3 discontinued by participant.
Part 2 an additional 54 were enrolled. Prior to receiving study drug: 3 discontinued by participant, 1 withdrew due to an AE, 2 screen failures, and 3 withdrew due to site closure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PK (BAX326 Then BeneFIX) Then Prophylaxis Then PK BAX326 Only</title>
          <description>Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 (75 ± 5 IU/kg) then BeneFIX (75 ± 5 IU/kg).
Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 (75 ± 5 IU/kg) only and same study participants as Study Part 1</description>
        </group>
        <group group_id="P2">
          <title>PK (BeneFIX Then BAX326) Then Prophylaxis Then PK BAX326 Only</title>
          <description>Study Part 1: Pharmacokinetic (PK) Crossover with BeneFIX (75 ± 5 IU/kg) then BAX326 (75 ± 5 IU/kg).
Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 (75 ± 5 IU/kg) only and same study participants as Study Part 1</description>
        </group>
        <group group_id="P3">
          <title>Study Part 2 Only: BAX326 Prophylaxis</title>
          <description>-Participants were only in Study Part 2 (i.e., did not participate in Study Parts 1 and 3)</description>
        </group>
        <group group_id="P4">
          <title>Study Part 2 Only: BAX326 On-Demand</title>
          <description>-Participants were only in Study Part 2 (i.e., did not participate in Study Parts 1 and 3)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1 -Pharmacokinetic Crossover</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14">BAX326 was mistakenly infused for second PK infusion (ie should have been BeneFIX) for 1 participant</participants>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2 -BAX326 Prophylaxis and On-demand</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">In Study Part 2 all 14 participants received Prophylaxis</participants>
                <participants group_id="P2" count="14">In Study Part 2 all 14 participants received Prophylaxis</participants>
                <participants group_id="P3" count="31">This group only participated in Study Part 2</participants>
                <participants group_id="P4" count="14">This group only participated in Study Part 2</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="29"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3 -Pharmacokinetic BAX326 Only</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14">Includes all participants who completed Part 1</participants>
                <participants group_id="P2" count="14">Includes all participants who completed Part 1</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Required Emergency Surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants Who Received Study Drug</title>
          <description>BAX326 : -Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX
Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Study Part 1- Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Per Dose</title>
        <description>Computed using the linear trapezoidal method. The concentration at 72 hours was interpolated from the two nearest sampling time points or extrapolated using the last quantifiable concentration and the terminal rate constant λz. λz was estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.</description>
        <time_frame>72 hours</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>BAX326</title>
          </group>
          <group group_id="O2">
            <title>BeneFIX</title>
          </group>
        </group_list>
        <measure>
          <title>Study Part 1- Area Under the Plasma Concentration Versus Time Curve From 0 to 72 Hours Per Dose</title>
          <description>Computed using the linear trapezoidal method. The concentration at 72 hours was interpolated from the two nearest sampling time points or extrapolated using the last quantifiable concentration and the terminal rate constant λz. λz was estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>(IU·hr/dL) / (IU/kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.30" lower_limit="11.20" upper_limit="15.95"/>
                    <measurement group_id="O2" value="13.42" lower_limit="11.08" upper_limit="15.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Bioequivalence will be established if 90% C.I. of ratio is contained completely in the margins of equivalence of 0.8 to 1.25.</non_inferiority_desc>
            <param_type>Ratio of Geometric Means</param_type>
            <param_value>1.063</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Parts 1 and 3: Area Under the Plasma Concentration/Time Curve From Time 0 to Infinity Per Dose (AUC0-∞/ Dose)</title>
        <description>Defined as (AUC0-t + Ct)/ λz/ dose, where t is the time of last quantifiable concentration, Ct is the last quantifiable concentration. λz will be estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
        <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Study Part 1: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Part 1: BeneFIX</title>
            <description>PK infusion with BeneFIX at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Study Part 3: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg
Study Part 3 only evaluated BAX326 (ie BeneFIX was not evaluated in Study Part 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Study Parts 1 and 3: Area Under the Plasma Concentration/Time Curve From Time 0 to Infinity Per Dose (AUC0-∞/ Dose)</title>
          <description>Defined as (AUC0-t + Ct)/ λz/ dose, where t is the time of last quantifiable concentration, Ct is the last quantifiable concentration. λz will be estimated from the slope of natural log-linear fitting to latter quantifiable concentrations, with largest adjusted R^2.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>(IU·hr)/ dL/ (IU/kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.07" lower_limit="13.43" upper_limit="17.48"/>
                    <measurement group_id="O2" value="15.26" lower_limit="13.71" upper_limit="17.05"/>
                    <measurement group_id="O3" value="17.38" lower_limit="14.17" upper_limit="20.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Parts 1 and 3: Mean Residence Time (MRT)</title>
        <description>Computed as Area under the moment curve 0-∞ (AUMC0-∞) / AUC0-∞- TI/2, where AUMC0-∞ will be determined in a similar manner as AUC0-∞ and TI represents infusion duration [hr]
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
        <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Study Part 1: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Part 1: BeneFIX</title>
            <description>PK infusion with BeneFIX at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Study Part 3: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg
Study Part 3 only evaluated BAX326 (ie BeneFIX was not evaluated in Study Part 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Study Parts 1 and 3: Mean Residence Time (MRT)</title>
          <description>Computed as Area under the moment curve 0-∞ (AUMC0-∞) / AUC0-∞- TI/2, where AUMC0-∞ will be determined in a similar manner as AUC0-∞ and TI represents infusion duration [hr]
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.93" lower_limit="26.45" upper_limit="31.50"/>
                    <measurement group_id="O2" value="30.59" lower_limit="28.13" upper_limit="34.84"/>
                    <measurement group_id="O3" value="29.04" lower_limit="28.00" upper_limit="32.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Parts 1 and 3: Clearance (CL)</title>
        <description>Computed as Dose/ AUC0-∞.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
        <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Study Part 1: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Part 1: BeneFIX</title>
            <description>PK infusion with BeneFIX at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Study Part 3: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg
Study Part 3 only evaluated BAX326 (ie BeneFIX was not evaluated in Study Part 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Study Parts 1 and 3: Clearance (CL)</title>
          <description>Computed as Dose/ AUC0-∞.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>dL/(kg·hr)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0622" lower_limit="0.0572" upper_limit="0.0745"/>
                    <measurement group_id="O2" value="0.0655" lower_limit="0.0587" upper_limit="0.0730"/>
                    <measurement group_id="O3" value="0.0576" lower_limit="0.0483" upper_limit="0.0706"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Parts 1 and 3: Incremental Recovery at Cmax (IR at Cmax)</title>
        <description>Defined as (Cmax - Cpre-infusion)/Dose, where maximum concentration (Cmax) will be determined as the highest concentration achieved within one hour after infusion.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
        <time_frame>0-30 minutes before infusion up to 1 hour post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Study Part 1: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Part 1: BeneFIX</title>
            <description>PK infusion with BeneFIX at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Study Part 3: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg
Study Part 3 only evaluated BAX326 (ie BeneFIX was not evaluated in Study Part 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Study Parts 1 and 3: Incremental Recovery at Cmax (IR at Cmax)</title>
          <description>Defined as (Cmax - Cpre-infusion)/Dose, where maximum concentration (Cmax) will be determined as the highest concentration achieved within one hour after infusion.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>(IU/dL) / (IU/kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" lower_limit="0.79" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.73" lower_limit="0.66" upper_limit="0.87"/>
                    <measurement group_id="O3" value="0.93" lower_limit="0.76" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental Recovery (IR) at 30 Minutes Over Time</title>
        <description>IR at 30 Minutes was measured at the following time points during the study:
Part 1 or Part 2, Exposure Day (ED) 1. (If participant was present for Study Part 1, then ED 1 from Part 1 was used. If Participant entered study in Study Part 2, then ED 1 from Part 2 was used.)
Part 2: Week 5
Part 2: Week 13
Part 2 or Part 3: Week 26 (Week 26 of study participation)
Study Completion or Termination Visit</description>
        <time_frame>0-30 minutes before infusion and 30 minutes post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 or Part 2, ED 1</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Week 5</title>
            <description>PK infusion with BeneFIX at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Week 13</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg
Study Part 3 only evaluated BAX326 (ie BeneFIX was not evaluated in Study Part 3)</description>
          </group>
          <group group_id="O4">
            <title>Part 2 or Part 3: Week 26</title>
          </group>
          <group group_id="O5">
            <title>Study Completion or Termination Visit</title>
          </group>
        </group_list>
        <measure>
          <title>Incremental Recovery (IR) at 30 Minutes Over Time</title>
          <description>IR at 30 Minutes was measured at the following time points during the study:
Part 1 or Part 2, Exposure Day (ED) 1. (If participant was present for Study Part 1, then ED 1 from Part 1 was used. If Participant entered study in Study Part 2, then ED 1 from Part 2 was used.)
Part 2: Week 5
Part 2: Week 13
Part 2 or Part 3: Week 26 (Week 26 of study participation)
Study Completion or Termination Visit</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>(IU/dL) / (IU/kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="0.7" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0.79" lower_limit="0.68" upper_limit="0.96"/>
                    <measurement group_id="O3" value="0.83" lower_limit="0.655" upper_limit="1.015"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.75" upper_limit="1.04"/>
                    <measurement group_id="O5" value="0.89" lower_limit="0.73" upper_limit="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Incremental Recovery (IR) at 30 Minutes Over Time</title>
        <description>The median changes in IR at 30 Minutes, calculated as the change in IR value from exposure day 1 (ED1).</description>
        <time_frame>0-30 minutes before infusion and 30 minutes post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Week 5</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Week 13</title>
          </group>
          <group group_id="O3">
            <title>Part 2 or Part 3: Week 26</title>
          </group>
          <group group_id="O4">
            <title>Study Completion or Termination Visit</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Incremental Recovery (IR) at 30 Minutes Over Time</title>
          <description>The median changes in IR at 30 Minutes, calculated as the change in IR value from exposure day 1 (ED1).</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>(IU/dL) / (IU/kg)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.09" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.075" lower_limit="-0.07" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.06" lower_limit="0.02" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0.12" lower_limit="0" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Parts 1 and 3: Half Life (T 1/2)</title>
        <description>Elimination phase half-life will be determined as ln2/ λz.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
        <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Study Part 1: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Part 1: BeneFIX</title>
            <description>PK infusion with BeneFIX at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Study Part 3: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg
Study Part 3 only evaluated BAX326 (ie BeneFIX was not evaluated in Study Part 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Study Parts 1 and 3: Half Life (T 1/2)</title>
          <description>Elimination phase half-life will be determined as ln2/ λz.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.58" lower_limit="20.98" upper_limit="29.68"/>
                    <measurement group_id="O2" value="26.28" lower_limit="22.51" upper_limit="29.46"/>
                    <measurement group_id="O3" value="24.59" lower_limit="19.68" upper_limit="29.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Parts 1 and 3: Volume of Distribution at Steady State (Vss)</title>
        <description>Vss computed as CL·MRT.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
        <time_frame>0-30 minutes before infusion up to 72 hours post-infusion</time_frame>
        <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
        <group_list>
          <group group_id="O1">
            <title>Study Part 1: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O2">
            <title>Study Part 1: BeneFIX</title>
            <description>PK infusion with BeneFIX at 75 ± 5 IU/kg</description>
          </group>
          <group group_id="O3">
            <title>Study Part 3: BAX326</title>
            <description>PK infusion with BAX326 at 75 ± 5 IU/kg
Study Part 3 only evaluated BAX326 (ie BeneFIX was not evaluated in Study Part 3)</description>
          </group>
        </group_list>
        <measure>
          <title>Study Parts 1 and 3: Volume of Distribution at Steady State (Vss)</title>
          <description>Vss computed as CL·MRT.
The objective of Study Part 3 was to re-evaluate the Pharmacokinetic (PK) parameters for BAX 326 after a period of 6 months of treatment, in participants who accumulated at least 30 EDs to BAX 326, and to compare them with those determined in the same participants participating in Study Part 1.</description>
          <population>Pharmacokinetic Per Protocol Analysis Set (PKPPAS)
-Participants who participated in Study Parts 1-3 and completed Study Part 1 without any major protocol deviations</population>
          <units>dL/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" lower_limit="1.56" upper_limit="2.30"/>
                    <measurement group_id="O2" value="1.98" lower_limit="1.76" upper_limit="2.51"/>
                    <measurement group_id="O3" value="1.74" lower_limit="1.49" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Part 2: Annualized Bleed Rate (ABR) During Treatment With BAX326</title>
        <description>ABR during prophylaxis (twice-weekly) in Part 2 was calculated as (Number of bleeding episodes/observed treatment period in days) * 365.25. The treatment period on prophylaxis was defined as time between the first and the last prophylactic infusions and ABR on prophylaxis was calculated for participants who received a minimum of 3 months of prophylactic treatment with BAX326.</description>
        <time_frame>Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks)</time_frame>
        <population>Full Analysis Set - Prophylactic cohort</population>
        <group_list>
          <group group_id="O1">
            <title>BAX326 Prophylaxis</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.
Participants received a minimum of three months prophylactic treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Study Part 2: Annualized Bleed Rate (ABR) During Treatment With BAX326</title>
          <description>ABR during prophylaxis (twice-weekly) in Part 2 was calculated as (Number of bleeding episodes/observed treatment period in days) * 365.25. The treatment period on prophylaxis was defined as time between the first and the last prophylactic infusions and ABR on prophylaxis was calculated for participants who received a minimum of 3 months of prophylactic treatment with BAX326.</description>
          <population>Full Analysis Set - Prophylactic cohort</population>
          <units>Bleeds per year</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Joint bleeding episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Joint bleeding episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous bleeding episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding episode caused by injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown cause of bleeding episode</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All bleeding episodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="0.0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Episodes Treated With 1, 2 or ≥3 Infusions of BAX326 by Bleeding Site and Cause</title>
        <description>The number of bleeding episodes treated with 1, 2, or ≥3 infusions of BAX326 to achieve adequate hemostasis. Only infusions required until resolution of bleed were considered.</description>
        <time_frame>Study Part 2 = 26 weeks ± 1 week (Study Part 2 began at week 3-5)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Bleeding Site: Target Joint</title>
          </group>
          <group group_id="O2">
            <title>Bleeding Site: Non-Target Joint</title>
          </group>
          <group group_id="O3">
            <title>Bleeding Site: All Joint</title>
          </group>
          <group group_id="O4">
            <title>Bleeding Site: Non-Joint</title>
          </group>
          <group group_id="O5">
            <title>Bleeding Cause: Spontaneous</title>
          </group>
          <group group_id="O6">
            <title>Bleeding Cause: Injury</title>
          </group>
          <group group_id="O7">
            <title>Bleeding Cause: Unknown</title>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Episodes Treated With 1, 2 or ≥3 Infusions of BAX326 by Bleeding Site and Cause</title>
          <description>The number of bleeding episodes treated with 1, 2, or ≥3 infusions of BAX326 to achieve adequate hemostasis. Only infusions required until resolution of bleed were considered.</description>
          <population>Full Analysis Set</population>
          <units>Bleeding episodes</units>
          <param>Number</param>
          <units_analyzed>bleeding episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>bleeding episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="130"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 infusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="122"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="84"/>
                    <measurement group_id="O6" value="50"/>
                    <measurement group_id="O7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 infusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 or more infusions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="16"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemostatic Efficacy at Resolution of All Bleeding Episodes (BEs) Treated With BAX326 by Bleeding Site and Cause</title>
        <description>Rating Scale for Treatment of BEs (4-point ordinal scale):
Excellent: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion required for the control of bleeding. Administration of further infusions to maintain hemostasis did not affect this scoring.
Good: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution.
Fair: Probable and/or slight relief of pain and slight improvement in signs of bleeding after single infusion. Required more than 1 infusion for complete resolution.
None: No improvement or condition worsens.</description>
        <time_frame>At bleed resolution throughout the study period of 22 months (Study Parts 1, 2, and 3)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Bleeding Site: Target Joint</title>
          </group>
          <group group_id="O2">
            <title>Bleeding Site: Non-Target Joint</title>
          </group>
          <group group_id="O3">
            <title>Bleeding Site: All Joint</title>
          </group>
          <group group_id="O4">
            <title>Bleeding Site: Non-Joint</title>
          </group>
          <group group_id="O5">
            <title>Bleeding Cause: Spontaneous</title>
          </group>
          <group group_id="O6">
            <title>Bleeding Cause: Injury</title>
          </group>
          <group group_id="O7">
            <title>Bleeding Cause: Unknown</title>
          </group>
        </group_list>
        <measure>
          <title>Hemostatic Efficacy at Resolution of All Bleeding Episodes (BEs) Treated With BAX326 by Bleeding Site and Cause</title>
          <description>Rating Scale for Treatment of BEs (4-point ordinal scale):
Excellent: Full relief of pain and cessation of objective signs of bleeding (eg, swelling, tenderness, and decreased range of motion in the case of musculoskeletal hemorrhage) after a single infusion. No additional infusion required for the control of bleeding. Administration of further infusions to maintain hemostasis did not affect this scoring.
Good: Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution.
Fair: Probable and/or slight relief of pain and slight improvement in signs of bleeding after single infusion. Required more than 1 infusion for complete resolution.
None: No improvement or condition worsens.</description>
          <population>Full Analysis Set</population>
          <units>Bleeding episodes</units>
          <param>Number</param>
          <units_analyzed>Bleeding episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="130"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="85"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="51"/>
                    <measurement group_id="O6" value="40"/>
                    <measurement group_id="O7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="75"/>
                    <measurement group_id="O6" value="45"/>
                    <measurement group_id="O7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Weight-adjusted Dose Per Bleeding Episode (BEs) of All BEs Treated With BAX326 by Bleeding Site and Cause</title>
        <time_frame>Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Bleeding Site: Target Joint</title>
          </group>
          <group group_id="O2">
            <title>Bleeding Site: Non-Target Joint</title>
          </group>
          <group group_id="O3">
            <title>Bleeding Site: All Joint</title>
          </group>
          <group group_id="O4">
            <title>Bleeding Site: Non-Joint</title>
          </group>
          <group group_id="O5">
            <title>Bleeding Cause: Spontaneous</title>
          </group>
          <group group_id="O6">
            <title>Bleeding Cause: Injury</title>
          </group>
          <group group_id="O7">
            <title>Bleeding Cause: Unknown</title>
          </group>
        </group_list>
        <measure>
          <title>Total Weight-adjusted Dose Per Bleeding Episode (BEs) of All BEs Treated With BAX326 by Bleeding Site and Cause</title>
          <population>Full Analysis Set</population>
          <units>IU/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Bleeding Episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="73"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="73"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Bleeding Episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="52"/>
                <count group_id="O5" value="130"/>
                <count group_id="O6" value="90"/>
                <count group_id="O7" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.5" lower_limit="48" upper_limit="97"/>
                    <measurement group_id="O2" value="59.0" lower_limit="46" upper_limit="97"/>
                    <measurement group_id="O3" value="56.5" lower_limit="47" upper_limit="97"/>
                    <measurement group_id="O4" value="68.7" lower_limit="50" upper_limit="130"/>
                    <measurement group_id="O5" value="52.3" lower_limit="45" upper_limit="92"/>
                    <measurement group_id="O6" value="70.0" lower_limit="48" upper_limit="116"/>
                    <measurement group_id="O7" value="56.5" lower_limit="51" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consumption of BAX326 Per Event Per Participant</title>
        <description>Weight-adjusted consumption of BAX326 by event per participant, i.e., for prophylactic treatment and for treatment of bleeds until resolution of bleed.</description>
        <time_frame>Study Part 2 = 26 weeks ± 1 week (Note: Study Part 1 = 2-4 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylactic Treatment</title>
          </group>
          <group group_id="O2">
            <title>Bleeding Treatment</title>
            <description>Includes all participants who received any infusions for bleeding treatment in the Full Analysis Set. (ie includes all On-demand arm (N=14) and 33 participants from the prophylaxis arm who experienced a bleeding episode)</description>
          </group>
        </group_list>
        <measure>
          <title>Consumption of BAX326 Per Event Per Participant</title>
          <description>Weight-adjusted consumption of BAX326 by event per participant, i.e., for prophylactic treatment and for treatment of bleeds until resolution of bleed.</description>
          <population>Full Analysis Set</population>
          <units>IU/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.5" lower_limit="46" upper_limit="52"/>
                    <measurement group_id="O2" value="87.1" lower_limit="56" upper_limit="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consumption of BAX326 Per Participant: Median Number of Infusions Per Month</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week (Prophylaxis and On-Demand period), Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Study Part 2 Only</description>
          </group>
          <group group_id="O2">
            <title>On-Demand</title>
            <description>Study Part 2 Only</description>
          </group>
        </group_list>
        <measure>
          <title>Consumption of BAX326 Per Participant: Median Number of Infusions Per Month</title>
          <population>Full Analysis Set</population>
          <units>Infusions</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="6" upper_limit="7"/>
                    <measurement group_id="O2" value="2.7" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Consumption of BAX326 Per Participant: Median Weight-adjusted Consumption Per Month</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week (Prophylaxis and On-Demand period), Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Study Part 2 Only</description>
          </group>
          <group group_id="O2">
            <title>On-Demand</title>
            <description>Study Part 2 Only</description>
          </group>
        </group_list>
        <measure>
          <title>Consumption of BAX326 Per Participant: Median Weight-adjusted Consumption Per Month</title>
          <population>Full Analysis Set</population>
          <units>IU/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347.8" lower_limit="320" upper_limit="396"/>
                    <measurement group_id="O2" value="167.3" lower_limit="102" upper_limit="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX)</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Inhibitory Antibodies to Factor IX (FIX)</title>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Total Binding Antibodies of Indeterminate Specificity (Within Assay Variability)</title>
        <description>Occurrence of total binding antibodies of indeterminate specificity (within assay variability) to FIX, antibodies to CHO proteins and rFurin is defined by a dilution of 2 or less increase as compared to levels at screening visit (e.g. negative to 1:20 or 1:40).</description>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Total Binding Antibodies of Indeterminate Specificity (Within Assay Variability)</title>
          <description>Occurrence of total binding antibodies of indeterminate specificity (within assay variability) to FIX, antibodies to CHO proteins and rFurin is defined by a dilution of 2 or less increase as compared to levels at screening visit (e.g. negative to 1:20 or 1:40).</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Binding Antibody to Factor IX (FIX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody to Chinese hamster ovary (CHO) Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody to recombinant Furin (rFurin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Treatment Related Total Binding Antibodies</title>
        <description>Occurrence of treatment related total binding antibodies to Factor IX (FIX), antibodies to Chinese hamster ovary (CHO) proteins, and recombinant furin (rFurin) is defined by more than 2-dilution increase as compared to levels at screening visit and confirmed specificity (e.g. negative to 1:80)</description>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Treatment Related Total Binding Antibodies</title>
          <description>Occurrence of treatment related total binding antibodies to Factor IX (FIX), antibodies to Chinese hamster ovary (CHO) proteins, and recombinant furin (rFurin) is defined by more than 2-dilution increase as compared to levels at screening visit and confirmed specificity (e.g. negative to 1:80)</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Binding Antibody to Factor IX (FIX)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody to Chinese hamster ovary (CHO) Protein</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antibody to recombinant Furin (rFurin)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Severe Allergic Reactions (e.g. Anaphylaxis)</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Severe Allergic Reactions (e.g. Anaphylaxis)</title>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Thrombotic Events</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Thrombotic Events</title>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Clinical Chemistry</title>
        <description>Clinically significant changes in chemistry assessments for Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bicarbonate, Bilirubin, Blood Urea Nitrogen, Chloride, Glucose, Potassium, Protein (Serum), Sodium.
Clinically Significant (CS) defined as:
1. The abnormal value constitutes an adverse event (AE) and,
2. The abnormal value is a symptom of or related to a disease that is already recorded as an AE in Case Report Form (CRF).</description>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Clinical Chemistry</title>
          <description>Clinically significant changes in chemistry assessments for Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bicarbonate, Bilirubin, Blood Urea Nitrogen, Chloride, Glucose, Potassium, Protein (Serum), Sodium.
Clinically Significant (CS) defined as:
1. The abnormal value constitutes an adverse event (AE) and,
2. The abnormal value is a symptom of or related to a disease that is already recorded as an AE in Case Report Form (CRF).</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Hematology</title>
        <description>Clinically significant changes in hematology assessments for Basophils, Basophils/Leukocytes, Eosinophils, Eosinophils/Leukocytes, Erythrocyte Mean Corpuscular Hemoglobin Concentration, Erythrocyte Mean Corpuscular Volume, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Lymphocytes/Leukocytes, Monocytes, Monocytes/Leukocytes, Neutrophils, Neutrophils/Leukocytes, Platelets,</description>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Hematology</title>
          <description>Clinically significant changes in hematology assessments for Basophils, Basophils/Leukocytes, Eosinophils, Eosinophils/Leukocytes, Erythrocyte Mean Corpuscular Hemoglobin Concentration, Erythrocyte Mean Corpuscular Volume, Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Lymphocytes/Leukocytes, Monocytes, Monocytes/Leukocytes, Neutrophils, Neutrophils/Leukocytes, Platelets,</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Vital Signs</title>
        <description>Clinically significant changes in vital signs assessments for pulse rate, systolic/diastolic blood pressure, respiratory rate, body temperature</description>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Vital Signs</title>
          <description>Clinically significant changes in vital signs assessments for pulse rate, systolic/diastolic blood pressure, respiratory rate, body temperature</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Thrombogenic Markers</title>
        <description>Clinically significant changes in thrombogenic markers assessments for thrombin-antithrombin (TAT), prothrombin fragment 1.2, and D-dimer as evaluated by an independent Data Monitoring Committee (DMC)</description>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Changes in Laboratory Parameters: Thrombogenic Markers</title>
          <description>Clinically significant changes in thrombogenic markers assessments for thrombin-antithrombin (TAT), prothrombin fragment 1.2, and D-dimer as evaluated by an independent Data Monitoring Committee (DMC)</description>
          <population>Full Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events (AEs) After BAX326 Treatment</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, and Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>AEs - Not Related</title>
          </group>
          <group group_id="O2">
            <title>AEs - Related</title>
            <description>Probable, possible, or unknown causality assessment of an AE will be counted as &quot;related&quot;.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events (AEs) After BAX326 Treatment</title>
          <population>Full Analysis Set</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious- Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious- Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious- Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious- Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) After BAX326 Treatment</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, and Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants With AEs - Not Related</title>
          </group>
          <group group_id="O2">
            <title>Participants With AEs - Related</title>
            <description>Probable, possible, or unknown causality assessment of an AE will be counted as &quot;related&quot;.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) After BAX326 Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious- Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious- Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious- Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious- Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Serious- Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Total Index Scores</title>
        <description>EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) Total Index Scores</title>
          <description>EQ-5D is a participant answered questionnaire scoring 5 dimensions - mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.16" lower_limit="0.7" upper_limit="0.8"/>
                    <measurement group_id="O2" value="0.75" spread="0.16" lower_limit="0.7" upper_limit="0.8"/>
                    <measurement group_id="O3" value="0.01" spread="0.18" lower_limit="-0.1" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.72" spread="0.14"/>
                    <measurement group_id="O5" value="0.73" spread="0.09"/>
                    <measurement group_id="O6" value="0.00" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7790</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8999</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQoL (Quality of Life)-5 Dimensions Visual Analogue Scale (EQ-5D VAS) Scores</title>
        <description>Participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better quality of life.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>EuroQoL (Quality of Life)-5 Dimensions Visual Analogue Scale (EQ-5D VAS) Scores</title>
          <description>Participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better quality of life.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.75" spread="24.89" lower_limit="50.0" upper_limit="75.0"/>
                    <measurement group_id="O2" value="68.22" spread="22.78" lower_limit="60.0" upper_limit="85.0"/>
                    <measurement group_id="O3" value="9.98" spread="25.41" lower_limit="-2.0" upper_limit="20.0"/>
                    <measurement group_id="O4" value="56.64" spread="25.97"/>
                    <measurement group_id="O5" value="62.07" spread="19.00"/>
                    <measurement group_id="O6" value="5.43" spread="24.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0056</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4130</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>General Pain Assessment Through a Visual Analog Scale (VAS)</title>
        <description>Participant rated assessment of health-related quality of life. The VAS Pain Scale rates current health state on a scale from 0 (no pain) to 100 (worst imaginable pain). For the pain scale, a higher score indicates worse pain.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>General Pain Assessment Through a Visual Analog Scale (VAS)</title>
          <description>Participant rated assessment of health-related quality of life. The VAS Pain Scale rates current health state on a scale from 0 (no pain) to 100 (worst imaginable pain). For the pain scale, a higher score indicates worse pain.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.67" spread="26.62"/>
                    <measurement group_id="O2" value="33.09" spread="25.90"/>
                    <measurement group_id="O3" value="0.35" spread="21.77"/>
                    <measurement group_id="O4" value="47.57" spread="30.82"/>
                    <measurement group_id="O5" value="39.93" spread="22.57"/>
                    <measurement group_id="O6" value="-7.64" spread="33.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9059</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4098</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short Form (36) Health Survey (SF-36): HRQoL 'Physical Component Score' (PCS)</title>
        <description>The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>Short Form (36) Health Survey (SF-36): HRQoL 'Physical Component Score' (PCS)</title>
          <description>The PCS is a summary scale of the dimensions physical functioning, role physical, bodily pain, and general health. The component score is normalized to a standard population. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.08" spread="9.39"/>
                    <measurement group_id="O2" value="41.35" spread="8.73"/>
                    <measurement group_id="O3" value="2.60" spread="7.72"/>
                    <measurement group_id="O4" value="37.38" spread="7.20"/>
                    <measurement group_id="O5" value="38.92" spread="8.53"/>
                    <measurement group_id="O6" value="1.54" spread="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0189</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2974</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL 'Mental Health' (MH)</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL 'Mental Health' (MH)</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.53" spread="9.46"/>
                    <measurement group_id="O2" value="49.67" spread="9.30"/>
                    <measurement group_id="O3" value="2.01" spread="11.17"/>
                    <measurement group_id="O4" value="47.24" spread="8.80"/>
                    <measurement group_id="O5" value="45.03" spread="9.96"/>
                    <measurement group_id="O6" value="-2.21" spread="8.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2009</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3552</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL Physical Functioning' (PF)</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL Physical Functioning' (PF)</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.20" spread="10.57"/>
                    <measurement group_id="O2" value="40.75" spread="10.14"/>
                    <measurement group_id="O3" value="0.68" spread="7.48"/>
                    <measurement group_id="O4" value="40.04" spread="10.57"/>
                    <measurement group_id="O5" value="39.87" spread="10.55"/>
                    <measurement group_id="O6" value="-0.16" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5143</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9223</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL Role-Physical (RP)</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL Role-Physical (RP)</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.39" spread="10.70"/>
                    <measurement group_id="O2" value="43.82" spread="8.67"/>
                    <measurement group_id="O3" value="3.47" spread="10.15"/>
                    <measurement group_id="O4" value="39.15" spread="8.13"/>
                    <measurement group_id="O5" value="37.45" spread="10.12"/>
                    <measurement group_id="O6" value="-1.70" spread="5.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0162</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3176</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL Role-Emotional</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL Role-Emotional</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.22" spread="11.45"/>
                    <measurement group_id="O2" value="44.80" spread="10.15"/>
                    <measurement group_id="O3" value="0.37" spread="11.74"/>
                    <measurement group_id="O4" value="40.93" spread="9.10"/>
                    <measurement group_id="O5" value="39.43" spread="11.57"/>
                    <measurement group_id="O6" value="-1.50" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8210</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5565</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL Bodily Pain</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL Bodily Pain</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.09" spread="10.21"/>
                    <measurement group_id="O2" value="45.72" spread="8.68"/>
                    <measurement group_id="O3" value="3.45" spread="9.95"/>
                    <measurement group_id="O4" value="36.89" spread="7.84"/>
                    <measurement group_id="O5" value="39.33" spread="8.91"/>
                    <measurement group_id="O6" value="2.44" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0146</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4048</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL Mental Health</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL Mental Health</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.52" spread="8.78"/>
                    <measurement group_id="O2" value="47.95" spread="8.84"/>
                    <measurement group_id="O3" value="2.44" spread="11.29"/>
                    <measurement group_id="O4" value="45.46" spread="10.57"/>
                    <measurement group_id="O5" value="42.64" spread="10.63"/>
                    <measurement group_id="O6" value="-2.82" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1258</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2567</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL Vitality</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL Vitality</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.07" spread="8.47"/>
                    <measurement group_id="O2" value="52.75" spread="8.88"/>
                    <measurement group_id="O3" value="2.46" spread="10.75"/>
                    <measurement group_id="O4" value="50.17" spread="5.63"/>
                    <measurement group_id="O5" value="50.89" spread="6.81"/>
                    <measurement group_id="O6" value="0.72" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1048</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6410</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL Social Functioning</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day (ED) 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day (ED) 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL Social Functioning</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.80" spread="10.54"/>
                    <measurement group_id="O2" value="44.60" spread="8.94"/>
                    <measurement group_id="O3" value="2.78" spread="10.78"/>
                    <measurement group_id="O4" value="43.42" spread="9.61"/>
                    <measurement group_id="O5" value="42.17" spread="9.80"/>
                    <measurement group_id="O6" value="-1.26" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0663</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4890</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-36: HRQoL General Health</title>
        <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>SF-36: HRQoL General Health</title>
          <description>Quality of life survey response as measured using the SF-36 questionnaire. Scores range from 0 to 100 with higher scores representing better health. There is no total overall score; scoring is done for both subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="53"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.84" spread="8.38"/>
                    <measurement group_id="O2" value="39.98" spread="9.03"/>
                    <measurement group_id="O3" value="2.20" spread="8.22"/>
                    <measurement group_id="O4" value="37.09" spread="10.47"/>
                    <measurement group_id="O5" value="39.07" spread="8.88"/>
                    <measurement group_id="O6" value="1.98" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0562</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3864</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pediatric Quality of Life Questionnaire (PedsQL) Physical Health Summary Score (Ages 12-16)</title>
        <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Quality of Life Questionnaire (PedsQL) Physical Health Summary Score (Ages 12-16)</title>
          <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.63" spread="13.26"/>
                    <measurement group_id="O2" value="54.69" spread="6.63"/>
                    <measurement group_id="O3" value="-10.94" spread="19.89"/>
                    <measurement group_id="O4" value="65.63">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O5" value="65.63">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O6" value="0.00">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5792</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pediatric Quality of Life Questionnaire (PedsQL) Psychosocial Health Summary Score (Ages 12-16)</title>
        <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Quality of Life Questionnaire (PedsQL) Psychosocial Health Summary Score (Ages 12-16)</title>
          <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.33" spread="11.79"/>
                    <measurement group_id="O2" value="55.83" spread="3.54"/>
                    <measurement group_id="O3" value="-7.50" spread="8.25"/>
                    <measurement group_id="O4" value="88.33">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O5" value="86.67">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O6" value="-1.67">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4208</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pediatric Quality of Life Questionnaire (PedsQL) Total Score (Ages 12-16)</title>
        <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>Pediatric Quality of Life Questionnaire (PedsQL) Total Score (Ages 12-16)</title>
          <description>The Peds-QL is a generic Health-Related Quality of Life (HR QoL) instrument designed specifically for a pediatric population. It captures the following domains: general health/activities, feelings/emotional, social functioning, school functioning. For this study, the Peds-QL for 12 to 16-year-old subjects was used. Higher scores indicate better quality of life (QOL) for all domains of the Peds-QL. This modular instrument uses a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, &amp; school functioning) are scored.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="1"/>
                <count group_id="O6" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.13" spread="12.30"/>
                    <measurement group_id="O2" value="55.43" spread="0.00"/>
                    <measurement group_id="O3" value="-8.70" spread="12.30"/>
                    <measurement group_id="O4" value="80.43">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O5" value="79.35">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O6" value="-1.09">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5000</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL) Disease-specific: Haem-A-QoL</title>
        <description>The Haem-A-QOL instrument has been developed and used in hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: physical health, sports/leisure, school/work, dealing with hemophilia, and outlook for the future. For the Haem-A-QOL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>Prophylaxis: End of Study</title>
          </group>
          <group group_id="O3">
            <title>Prophylaxis: Change From Baseline</title>
          </group>
          <group group_id="O4">
            <title>On-Demand: Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
          <group group_id="O5">
            <title>On-Demand: End of Study</title>
          </group>
          <group group_id="O6">
            <title>On-Demand: Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>Health-Related Quality of Life (HRQoL) Disease-specific: Haem-A-QoL</title>
          <description>The Haem-A-QOL instrument has been developed and used in hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: physical health, sports/leisure, school/work, dealing with hemophilia, and outlook for the future. For the Haem-A-QOL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.68" spread="15.33"/>
                    <measurement group_id="O2" value="37.85" spread="16.57"/>
                    <measurement group_id="O3" value="-3.52" spread="12.81"/>
                    <measurement group_id="O4" value="41.65" spread="15.19"/>
                    <measurement group_id="O5" value="41.37" spread="16.64"/>
                    <measurement group_id="O6" value="-0.28" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0633</p_value>
            <method>Paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9363</p_value>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-Related Quality of Life (HRQoL) Disease-specific: Haemo-QoL - Participants On-Demand (Ages 12-16)</title>
        <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.</description>
        <time_frame>Baseline at either Study Part 1, or Study Part 2, and End of Study (study weeks 29-31)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1 or Part 2, Exposure Day 1 (Baseline)</title>
          </group>
          <group group_id="O2">
            <title>End of Study</title>
          </group>
          <group group_id="O3">
            <title>Change From Baseline</title>
          </group>
        </group_list>
        <measure>
          <title>Health-Related Quality of Life (HRQoL) Disease-specific: Haemo-QoL - Participants On-Demand (Ages 12-16)</title>
          <description>The Haemo-QoL is a quality of life (QoL) assessment instrument for children and adolescents with haemophilia. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. For the Haemo-QoL, higher scores indicate a worse quality of life. Scores on a scale range between 0 and 100.</description>
          <population>Full Analysis Set</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.00">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O2" value="40.00">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                    <measurement group_id="O3" value="0.00">Sample size = 1, therefore not possible to calculate a standard deviation.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Resource Use - Number of Hospitalizations</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>On-Demand</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
        </group_list>
        <measure>
          <title>Health Resource Use - Number of Hospitalizations</title>
          <population>Full Analysis Set</population>
          <units>Hospitalizations</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 1 - Pharmacokinetics (N= 28, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Exposure Day 1 (N= 31, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 5 (N= 57, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 13 (N= 56, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 26 (N= 30, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 2 at Week 26</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 3 (N= 25, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 3</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 20, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Study Visit (N= 1, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm with an unscheduled Study Visit</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Resource Use - Total Days of Hospital Stay</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Resource Use - Total Days of Hospital Stay</title>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 2: Week 5 (N= 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0" lower_limit="46" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 13 (N= 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="23" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 3 (N= 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Resource Use - Emergency Room Visits</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>On-Demand</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
        </group_list>
        <measure>
          <title>Health Resource Use - Emergency Room Visits</title>
          <population>Full Analysis Set</population>
          <units>Visits</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 1 - Pharmacokinetics (N= 28, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Exposure Day 1 (N= 31, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 5 (N= 57, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 13 (N= 56, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 26 (N= 30, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 2 at Week 26</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 3 (N= 25, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 3</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 20, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Study Visit (N= 1, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm with an unscheduled Study Visit</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Resource Use - Unscheduled Doctor's Office Visits</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>On-Demand</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
        </group_list>
        <measure>
          <title>Health Resource Use - Unscheduled Doctor's Office Visits</title>
          <population>Full Analysis Set</population>
          <units>Visits</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 1 - Pharmacokinetics (N= 28, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Exposure Day 1 (N= 31, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 5 (N= 57, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 13 (N= 56, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 26 (N= 30, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 2 at Week 26</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 3 (N= 25, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 3</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 20, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Study Visit (N= 1, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1" upper_limit="1"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm with an unscheduled Study Visit</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Resource Use - Days Lost From Work or School</title>
        <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Prophylaxis</title>
            <description>Prophylactic treatment of 50 IU/kg BAX326 twice weekly. The dose range is 40-60 IU/kg and may be increased up to 75 IU/kg, if required.</description>
          </group>
          <group group_id="O2">
            <title>On-Demand</title>
            <description>On-Demand Dosing and Frequency (Guidance):
Early hemarthrosis, muscle bleed, oral bleed= FIX level required(%) 20-40 IU/dL. Repeat every 24 hours. Duration: at least 1 day, until bleeding episode as indicated by pain is resolved or healing is achieved
More extensive hemarthrosis, muscle bleed, hematoma= FIX level required(%) 30-60 IU/dL. Repeat infusion every 24 hours for 3-4 days or more until pain and acute disability are resolved
Life threatening hemorrhages= FIX level required(%) 60-100 IU/dL. Repeat infusion every 8-24 hours until threat resolves
Required dose calculated using IR determined of first 16 participants who completed Part 1 according to:
Body weight (kg) x desired FIX rise (%) (IU/dL) x {reciprocal of observed recovery}
Given an anticipated recovery of 0.8 [IU/dl]/[IU/kg], required units calculated by:
Body weight (kg) x desired FIX rise (%or (IU/dL) x 1.3 IU/kg
Amount administered &amp; frequency should be oriented to individual clinical effectiveness</description>
          </group>
        </group_list>
        <measure>
          <title>Health Resource Use - Days Lost From Work or School</title>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Part 1 - Pharmacokinetics (N= 28, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Exposure Day 1 (N= 31, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 5 (N= 57, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 13 (N= 56, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2: Week 26 (N= 30, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 2 at Week 26</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 3 (N= 25, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm in Study Part 3</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completion/Termination (N= 20, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Study Visit (N= 1, NA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="NA">There were no participants from the On-Demand arm with an unscheduled Study Visit</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study Part 1 = 2-4 weeks, Study Part 2 = 26 weeks ± 1 week, Study Part 3 = 1 week (Total = 29-31 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BAX326</title>
          <description>BAX326: -Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX
Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis B Core Antibody Positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Immunology Test Abnormal</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Agreements may vary with individual PIs, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or up to 3 years after study completion. Baxter requires a review of results communications (eg for confidential information) ≥60 days prior to submission/communication. Baxter may request additional delay of ≤180 days(e.g., for intellectual property protection). Prior authorization may be required.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brigitt Abbuehl, MD, Global Medical Director, Hematology/Hemophilia</name_or_title>
      <organization>Baxter Innovations GmbH</organization>
      <email>brigitt_abbuehl@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

